James Beck, PhD, on Identifying Genetic Variants of Parkinson Disease

Video

The chief scientific officer and senior vice president of the Parkinson’s Foundation discussed mutations the Parkinson’s Foundation has identified.

“What we hope to do by our initiative is not only advanced the potential for precision medicine therapies but change the standard of care for those living with Parkinson's disease.”

The Parkinson’s Foundation is aiming to increase the genetics knowledge base of people with Parkinson disease (PD) as precision medicine and gene therapies grow in prominence and are starting to be explored and tested in more fields with the launce of PDGENEration (NCT04057794).

The Foundation believes genetic counseling and testing for people with PD needs to become part of the standard of care to enable future genetic medicine treatment or participation in clinical trials. Currently, the genetic status of many patients with PD remainsunknown since most have not been genetically tested. Participation in PDGENEration is available at-home or in-person at sites across the US to people with PD.

CGTLive spoke with James Beck, PhD, chief scientific officer and senior vice president, Parkinson’s Foundation, to learn more about the findings that PDGENEration has discovered. Neurologists seeking more information about PD GENEration can visit PDGENEration.com or email [email protected] questions about enrollment.

REFERENCE
Parkinson’s Foundation announces major expansion of PD GENErationstudy, increasing access to genetic testing and counseling across the U.S. News release. Parkinson’s Foundation. May 3, 2022. https://www.parkinson.org/about-us/press-release/Parkinsons-Foundation-expansion-PD-GENEration-study
Recent Videos
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Laura Aguilar MD, PhD, the chief medical officer of Diakonos Oncology
Jamie Jacobs, PhD, the program director of the center for psychiatric oncology & behavioral sciences at Mass General Cancer Center
Laura Aguilar MD, PhD, the chief medical officer of Diakonos Oncology
Sarah Hein, PhD, the chief executive officer and cofounder of March Biosciences
Brian Kim, MBA, the chief executive officer of Mission Bio
Peter Cook, PhD, a senior research scientist at Seattle Children’s Research Institute
Nicholas Giovannone, PhD, a senior principal scientist at Regeneron
Related Content
© 2025 MJH Life Sciences

All rights reserved.